1. A 28-year-old man with cystic fibrosis (CF) carries one F508del allele and one W1282X allele (a class I nonsense mutation) and has been on elexacaftor-tezacaftor-ivacaftor (ETI) for 22 months with FEV1% predicted stable at 61%. He is admitted after a first unprovoked generalized tonic-clonic seizure. Neurology evaluates him, rules out structural or metabolic causes, and recommends initiating an antiepileptic drug. The neurology team proposes carbamazepine. Which of the following best identifies the pharmacokinetic risk of carbamazepine in this patient and the most appropriate anticonvulsant strategy?
A) Carbamazepine is a moderate inhibitor of cytochrome P450 isoform CYP3A4 (CYP3A4) and would raise ivacaftor plasma concentrations modestly; the correct management is to reduce ETI to every-other-day dosing for the duration of carbamazepine therapy, using the same adjustment protocol applied for azole antifungal co-administration.
B) Carbamazepine is a potent inducer of CYP3A4 and would markedly reduce ivacaftor plasma concentrations to sub-therapeutic levels, potentially eliminating CFTR potentiation and compromising ETI efficacy; carbamazepine should be avoided with any ivacaftor-containing regimen, and an alternative anticonvulsant that does not induce CYP3A4 — such as levetiracetam or lamotrigine — should be selected in consultation with neurology.
C) Carbamazepine has no clinically significant pharmacokinetic interaction with ETI because ivacaftor is metabolized by CYP2D6, not CYP3A4; carbamazepine's CYP3A4 induction affects other drug classes but does not alter ivacaftor plasma concentrations, making co-administration safe without any ETI dose adjustment.
D) Carbamazepine is a strong CYP3A4 inducer but the interaction is clinically offset by elexacaftor's own mild CYP3A4 inhibition, which compensates for the induction and maintains net ivacaftor concentrations in the therapeutic range; no dose adjustment is needed provided elexacaftor and carbamazepine are taken simultaneously to allow competitive binding at the CYP3A4 active site.
E) Carbamazepine induces CYP3A4 and reduces ivacaftor concentrations, but this interaction is manageable by doubling the ETI morning dose to two dual-corrector tablets plus one extra ivacaftor tablet while maintaining the standard evening ivacaftor dose; this dose escalation protocol compensates for the induction-driven increase in ivacaftor clearance.
ANSWER: B
Rationale:
Carbamazepine is a potent inducer of cytochrome P450 isoform CYP3A4 (CYP3A4), the primary hepatic enzyme responsible for ivacaftor metabolism. The ivacaftor and ETI prescribing labels explicitly classify strong CYP3A4 inducers — including carbamazepine, phenytoin, rifampin, and St. John's wort — as agents that should be avoided with any ivacaftor-containing regimen, because co-administration markedly accelerates ivacaftor metabolism, reducing plasma concentrations to potentially sub-therapeutic levels and compromising CFTR potentiation. Unlike the CYP3A4 inhibitor scenario (where the labeled every-other-day dose adjustment compensates for reduced ivacaftor clearance), there is no established dose-escalation protocol that reliably compensates for strong CYP3A4 inducer-driven clearance acceleration; the correct strategy is to avoid the strong inducer entirely and select an alternative anticonvulsant. Levetiracetam and lamotrigine are anticonvulsants that do not induce CYP3A4 and can be co-administered with ETI without pharmacokinetic interaction; the choice between them should be made in neurology consultation based on seizure type, tolerability, and patient-specific factors.
Option A: Option A is incorrect because carbamazepine is a strong CYP3A4 inducer, not an inhibitor; the every-other-day adjustment is the labeled protocol for CYP3A4 inhibitors (which raise ivacaftor concentrations), not for inducers (which lower them), and applying the inhibitor adjustment protocol to an inducer interaction is mechanistically inappropriate.
Option C: Option C is incorrect because ivacaftor is metabolized primarily by CYP3A4, not CYP2D6; carbamazepine's CYP3A4 induction does substantially reduce ivacaftor concentrations, and the claim of pharmacokinetic insensitivity is factually wrong.
Option D: Option D is incorrect because elexacaftor does not have clinically meaningful CYP3A4 inhibitory activity that would offset carbamazepine's induction; no competitive binding compensation mechanism of this kind exists for this drug combination.
Option E: Option E is incorrect because doubling the ETI morning dose is not a labeled or pharmacokinetically validated management strategy for strong CYP3A4 inducer co-administration; the preferred approach is avoidance of the inducer, and dose escalation without validated pharmacokinetic modeling risks unpredictable ivacaftor exposure.
2. A 32-year-old woman with cystic fibrosis (CF) homozygous for F508del on elexacaftor-tezacaftor-ivacaftor (ETI) is diagnosed with CF-related diabetes (CFRD) after an oral glucose tolerance test (OGTT) shows a 2-hour plasma glucose of 218 mg/dL. Her body mass index (BMI) is 19.2 kg/m², and her primary care physician proposes initiating metformin because she is not obese and has no ketonuria, leading him to suspect she has type 2 diabetes mellitus rather than CFRD. Her CF team disagrees and recommends insulin instead. Which of the following best explains the pathophysiological basis of CFRD that makes insulin the preferred first-line treatment and metformin a poor fit for this patient?
A) Metformin is contraindicated in CFRD specifically because CF patients have impaired renal tubular secretion of metformin due to chronic aminoglycoside exposure, causing metformin accumulation and lactic acidosis risk at standard doses; insulin avoids this renal clearance problem entirely.
B) CFRD is caused by autoimmune destruction of pancreatic beta cells identical to type 1 diabetes mellitus, and metformin is ineffective in autoimmune diabetes because it targets hepatic gluconeogenesis rather than the immune-mediated insulin deficiency; insulin replacement is required from diagnosis because no residual beta-cell function remains.
C) Metformin's mechanism of action requires functional CFTR expression in hepatocytes to activate AMP-activated protein kinase (AMPK) signaling; in CFRD patients, absent hepatic CFTR eliminates the drug's target and renders metformin pharmacodynamically ineffective regardless of the degree of insulin resistance present.
D) CFRD results primarily from progressive destruction of pancreatic islet cells by advancing pancreatic exocrine fibrosis, producing relative insulin deficiency rather than the insulin resistance that characterizes type 2 diabetes mellitus; insulin therapy directly replaces the deficient hormone, addresses the underlying physiology, and may provide anabolic benefit in a nutritionally vulnerable population, whereas metformin — which acts by reducing hepatic glucose output and improving insulin sensitivity — is poorly matched to a condition driven by inadequate insulin secretion rather than peripheral resistance.
E) Metformin is avoided in CFRD because all CF patients receiving inhaled tobramycin for Pseudomonas aeruginosa suppression have elevated systemic aminoglycoside levels that competitively inhibit the organic cation transporter 2 (OCT2) responsible for metformin renal elimination, raising metformin plasma concentrations to toxic levels within the first week of co-administration.
ANSWER: D
Rationale:
CF-related diabetes (CFRD) has a pathophysiology fundamentally distinct from type 2 diabetes mellitus. In CF, progressive exocrine pancreatic fibrosis — driven by the accumulation of inspissated secretions from defective CFTR-mediated ductal bicarbonate and fluid secretion — destroys not only the exocrine acinar cells responsible for digestive enzyme production but also the endocrine islet cells interspersed within the pancreatic parenchyma, including insulin-secreting beta cells. The result is relative insulin deficiency: the pancreas cannot secrete sufficient insulin to meet physiological demand, particularly during the postprandial period and during the increased metabolic demands of pulmonary exacerbations. This is categorically different from the pathophysiology of type 2 diabetes mellitus, where the primary defect is peripheral tissue insulin resistance (in muscle, liver, and adipose tissue) with compensatory hyperinsulinemia in the early stages. Metformin acts primarily by activating AMP-activated protein kinase (AMPK) in the liver, reducing hepatic gluconeogenesis and improving insulin sensitivity in peripheral tissues — mechanisms targeted at insulin resistance, which is not the dominant defect in CFRD. Insulin therapy, by contrast, directly replaces the deficient hormone, provides glucose control throughout the day including during exacerbation-related stress hyperglycemia, and may have anabolic benefits in a patient population prone to malnutrition and muscle catabolism. This patient's normal BMI further supports insulin deficiency (not insulin resistance) as the dominant mechanism.
Option A: Option A is incorrect because CFRD patients do not have a specific contraindication to metformin based on impaired renal metformin secretion from aminoglycoside exposure; while renal function monitoring is relevant in CF, the primary reason insulin is preferred over metformin in CFRD is pathophysiological mismatch, not a pharmacokinetic renal clearance concern.
Option B: Option B is incorrect because CFRD is not caused by autoimmune beta-cell destruction; the mechanism is progressive pancreatic fibrosis, not the autoimmune T-cell-mediated islet attack that characterizes type 1 diabetes mellitus, and some residual beta-cell function is typically preserved in early CFRD.
Option C: Option C is incorrect because metformin's mechanism of action through AMPK activation in hepatocytes does not require CFTR expression; CFTR is not a component of the metformin pharmacodynamic pathway, and this mechanistic rationale is fabricated.
Option E: Option E is incorrect because inhaled tobramycin used for airway suppression of Pseudomonas aeruginosa achieves minimal systemic absorption and does not produce systemic aminoglycoside levels sufficient to clinically inhibit OCT2-mediated metformin renal elimination; this interaction scenario is not an established clinical concern.
3. A 27-year-old woman with cystic fibrosis (CF) homozygous for F508del has been on lumacaftor-ivacaftor for 8 months. She presents to clinic with 5 days of progressive jaundice, right upper quadrant discomfort, and nausea. Laboratory results show alanine aminotransferase (ALT) at 6.2 times the upper limit of normal (ULN), aspartate aminotransferase (AST) at 5.8 times the ULN, and total bilirubin elevated at 3.1 mg/dL. Viral hepatitis serologies are negative. Which of the following correctly identifies the labeled interrupt threshold that applies to this patient and the appropriate immediate management?
A) This patient meets the labeled interrupt threshold for symptomatic hepatotoxicity: the lumacaftor-ivacaftor prescribing label specifies that ALT or AST exceeding 3 times the ULN with symptoms of liver toxicity warrants drug interruption; with ALT at 6.2 times the ULN accompanied by jaundice, right upper quadrant pain, and nausea, lumacaftor-ivacaftor must be interrupted immediately and liver function reassessed before any decision about rechallenge or permanent discontinuation.
B) This patient does not yet meet the labeled interrupt threshold because the labeled criterion for symptomatic hepatotoxicity requires ALT or AST to exceed 10 times the ULN regardless of symptoms; at 6.2 times the ULN the drug should be continued with weekly LFT monitoring and dietary fat restriction while the underlying cause is investigated.
C) The appropriate management is to reduce the lumacaftor-ivacaftor dose by half and add ursodeoxycholic acid (UDCA) 15 mg/kg/day as hepatoprotection while investigating the cause; full drug interruption is reserved for patients with concurrent coagulopathy or encephalopathy indicating acute liver failure, which this patient does not have.
D) Because this patient has CF-related liver disease as a known comorbidity, transaminase elevations up to 8 times the ULN with mild jaundice are within the acceptable range of expected disease-related variation; lumacaftor-ivacaftor should be continued and the elevated LFTs attributed to CF hepatopathy rather than drug-induced liver injury.
E) The labeled threshold for lumacaftor-ivacaftor interruption applies only to patients with pre-existing liver disease; in patients without pre-existing hepatic disease, the drug can be continued until ALT or AST exceeds 10 times the ULN with symptoms, because the hepatotoxicity risk profile differs substantially between patients with and without baseline liver disease.
ANSWER: A
Rationale:
The prescribing label for lumacaftor-ivacaftor — as well as elexacaftor-tezacaftor-ivacaftor and other ivacaftor-containing regimens — specifies two hepatotoxicity interrupt thresholds: ALT or AST exceeding five times the upper limit of normal (ULN) in the absence of hepatotoxicity symptoms, or ALT or AST exceeding three times the ULN in the presence of symptoms of hepatotoxicity (jaundice, right upper quadrant pain, nausea, vomiting). This patient has ALT at 6.2 times the ULN and AST at 5.8 times the ULN accompanied by all three classic hepatotoxicity symptoms — jaundice, right upper quadrant discomfort, and nausea — and therefore meets both the symptomatic threshold (ALT >3× ULN with symptoms) and the asymptomatic threshold (ALT >5× ULN) simultaneously. Lumacaftor-ivacaftor must be interrupted immediately. After interruption, liver function should be reassessed serially; if LFTs normalize, specialist-guided rechallenge at lower or escalating doses may be feasible for some patients, while permanent discontinuation is appropriate if LFTs do not improve or if rechallenge produces recurrent elevation.
Option B: Option B is incorrect because the labeled symptomatic interrupt threshold is 3 times the ULN with symptoms, not 10 times the ULN regardless of symptoms; 10 times the ULN is not a labeled threshold, and continuing the drug in a symptomatic patient with ALT at 6.2× ULN would be unsafe and contrary to labeling.
Option C: Option C is incorrect because dose reduction combined with ursodeoxycholic acid is not the labeled management for symptomatic drug-induced transaminase elevation meeting the interrupt threshold; the label specifies interruption, and UDCA co-administration is not a guideline-recommended strategy for managing CFTR modulator hepatotoxicity.
Option D: Option D is incorrect because CF-related liver disease does not raise the acceptable upper limit of drug-induced transaminase elevation; symptomatic hepatotoxicity with bilirubin elevation in the context of initiating a CFTR modulator requires drug interruption and evaluation regardless of the patient's baseline hepatic status.
Option E: Option E is incorrect because the labeled interrupt thresholds apply to all patients on CFTR modulators regardless of pre-existing liver disease status; the label does not specify different thresholds for patients with and without baseline liver disease, and patients with CF-related liver disease actually require more frequent monitoring precisely because of their greater hepatic vulnerability.
4. A pharmacology student asks why a patient with G551D cystic fibrosis transmembrane conductance regulator (CFTR) mutation responds to ivacaftor monotherapy with a 10.6 percentage-point forced expiratory volume in one second as percent predicted (FEV1% predicted) improvement, while a patient homozygous for F508del on the same ivacaftor monotherapy shows essentially no benefit. Both patients have CFTR dysfunction — why does the same potentiator produce such dramatically different outcomes based on mutation class?
A) G551D patients respond to ivacaftor because the G551D mutation produces a CFTR protein with a very short endoplasmic reticulum (ER) retention time, allowing it to pass quickly through quality control and reach the apical membrane in large quantities; F508del CFTR has a longer ER retention time but still reaches the membrane in sufficient amounts for potentiation — the difference in response is due to differential ivacaftor binding affinity at the G551D versus F508del gating site.
B) G551D CFTR is degraded more slowly than F508del CFTR at the apical membrane, giving ivacaftor more time to act on surface-expressed channels; F508del CFTR is rapidly internalized after reaching the membrane, reducing the available target for ivacaftor potentiation and explaining the blunted response in F508del patients without corrector pre-treatment.
C) G551D CFTR folds normally and traffics to the apical membrane in normal amounts — the protein is present at the cell surface in full abundance — but cannot open appropriately due to a gating defect at the nucleotide-binding domain; because the pharmacological target for ivacaftor (surface-expressed CFTR with a gating defect) is fully available, potentiation alone produces dramatic benefit. F508del CFTR undergoes extensive ER-associated degradation and reaches the apical membrane in negligible amounts without a corrector; ivacaftor has essentially no surface-expressed F508del channel to potentiate, explaining why monotherapy produces no meaningful benefit in F508del patients.
D) G551D and F508del CFTR are both present at the apical membrane in equivalent amounts, but G551D CFTR has a higher intrinsic affinity for ivacaftor at its binding site due to the aspartate substitution at position 551, which creates a structural pocket that accommodates ivacaftor more tightly; F508del CFTR has a normal ivacaftor binding site but the deleted phenylalanine sterically blocks ivacaftor access in the uncorrected protein.
E) Ivacaftor is effective in G551D patients because G551D is a class II processing mutation that produces misfolded protein which retains gating capacity once it reaches the membrane; the misfolding is mild enough that a small amount of G551D CFTR escapes ER quality control without a corrector, and the potentiator amplifies this residual surface activity, whereas F508del misfolding is more severe and no protein escapes without corrector assistance.
ANSWER: C
Rationale:
The mechanistic basis for the dramatically different responses to ivacaftor monotherapy in G551D versus F508del patients lies in the availability of the pharmacological target — surface-expressed CFTR — at the apical epithelial membrane. G551D is a class III gating mutation: the G551D amino acid substitution (glycine to aspartate at position 551 in nucleotide-binding domain 1, NBD1) impairs adenosine triphosphate (ATP) binding and channel opening, but the protein folds and traffics normally through the endoplasmic reticulum (ER) and Golgi apparatus to the apical cell surface in normal or near-normal quantities. The pharmacological target for ivacaftor — CFTR already present at the membrane with a gating defect — is therefore fully available, and the potentiator produces a large increase in chloride conductance by dramatically increasing the channel open probability. F508del is a class II processing mutation: the phenylalanine-508 deletion produces a misfolded CFTR protein that is recognized by the ER quality control machinery (Hsp70/Hsp90 chaperone system), ubiquitinated, and targeted for proteasomal degradation through ER-associated degradation (ERAD) before it can complete trafficking to the apical membrane. In the absence of a corrector, essentially no F508del CFTR reaches the surface in meaningful amounts; ivacaftor given as monotherapy to an F508del patient has no surface-expressed channel to potentiate, and the therapeutic benefit is negligible.
Option A: Option A is incorrect because G551D CFTR's differential response to ivacaftor is not due to ER retention time or differential binding affinity; G551D CFTR traffics normally (not via a shortened ER retention), and F508del CFTR does not reach the membrane in meaningful amounts even with prolonged transit.
Option B: Option B is incorrect because differential apical membrane internalization rates are not the established mechanism distinguishing G551D from F508del responses; the primary distinction is whether CFTR reaches the surface at all, not its surface lifetime once there.
Option D: Option D is incorrect because G551D and F508del CFTR are not present at the apical membrane in equivalent amounts in the uncorrected state; F508del CFTR is largely absent from the surface without corrector rescue, and differential ivacaftor binding affinity based on the aspartate substitution is not the mechanism of differential response.
Option E: Option E is incorrect because G551D is a class III gating mutation, not a class II processing mutation; G551D CFTR is not misfolded and does not require ER escape from quality control — it traffics normally, which is precisely why potentiation alone is sufficient.
5. A 35-year-old woman with cystic fibrosis (CF) homozygous for F508del underwent liver transplantation 3 years ago for CF-related cirrhosis and is maintained on tacrolimus with stable trough levels of 9 ng/mL. Her pulmonologist wants to initiate a CFTR corrector-potentiator regimen. Elexacaftor-tezacaftor-ivacaftor (ETI) is available but the team is also considering lumacaftor-ivacaftor because of a prior formulary restriction. The transplant hepatologist expresses concern about drug interactions. Which of the following best explains why ETI or tezacaftor-ivacaftor is strongly preferred over lumacaftor-ivacaftor for this patient, integrating both the pharmacokinetic interaction and its clinical consequence?
A) Lumacaftor-ivacaftor is preferred over ETI in post-transplant patients because lumacaftor's CYP3A4 induction reduces tacrolimus plasma concentrations to safer, lower levels, decreasing tacrolimus-associated nephrotoxicity risk while maintaining adequate immunosuppression through compensatory upregulation of tacrolimus's calcineurin inhibitor activity.
B) ETI is preferred because elexacaftor inhibits the renal organic anion transporter responsible for tacrolimus excretion, maintaining tacrolimus trough levels within the therapeutic range despite lumacaftor's concomitant CYP3A4 induction; this pharmacokinetic balance is lost if lumacaftor-ivacaftor is used without elexacaftor.
C) Lumacaftor-ivacaftor and ETI carry equivalent tacrolimus interaction risk because all three CFTR correctors — lumacaftor, tezacaftor, and elexacaftor — are equally potent CYP3A4 inducers; the transplant hepatologist's concern applies equally to any corrector-containing regimen and should not influence regimen selection between the two.
D) ETI is preferred because ivacaftor is a moderate CYP3A4 inhibitor that partially offsets lumacaftor's CYP3A4 induction in the triple combination, maintaining tacrolimus concentrations closer to baseline than lumacaftor-ivacaftor alone; in the dual combination, this offsetting inhibition is absent, making lumacaftor-ivacaftor more dangerous for tacrolimus co-administration than ETI.
E) Lumacaftor is a strong CYP3A4 inducer that substantially accelerates tacrolimus metabolism, reducing tacrolimus trough concentrations and risking acute allograft rejection in a post-transplant patient dependent on stable therapeutic immunosuppression; tezacaftor and elexacaftor do not induce CYP3A4, so tezacaftor-ivacaftor or ETI eliminates this dangerous interaction and is strongly preferred for this patient.
ANSWER: E
Rationale:
The critical pharmacokinetic distinction that makes tezacaftor-ivacaftor or ETI strongly preferred over lumacaftor-ivacaftor in this post-transplant patient is lumacaftor's strong CYP3A4 induction. Tacrolimus is a narrow therapeutic index calcineurin inhibitor metabolized primarily by cytochrome P450 isoform CYP3A4 (CYP3A4) in the liver and intestinal wall. When lumacaftor — a potent CYP3A4 inducer — is co-administered, it markedly accelerates tacrolimus metabolism, reducing tacrolimus trough concentrations below the therapeutic range (typically 5–15 ng/mL in maintenance transplant patients) and risking acute cellular rejection of the transplanted liver. For a patient 3 years post-liver-transplantation with stable tacrolimus troughs of 9 ng/mL, even a partial reduction in tacrolimus exposure represents a clinically dangerous immunosuppressive gap. Tezacaftor and elexacaftor do not induce CYP3A4; when either tezacaftor-ivacaftor or ETI is used instead, tacrolimus pharmacokinetics are not meaningfully affected by the corrector components, and stable immunosuppression is maintained. This is one of the most important clinical reasons tezacaftor-ivacaftor was preferred over lumacaftor-ivacaftor for patients on CYP3A4-sensitive narrow therapeutic index drugs.
Option A: Option A is incorrect because reducing tacrolimus concentrations below therapeutic levels is not beneficial; it directly risks allograft rejection, which is a life-threatening complication in a post-liver-transplant patient, and lumacaftor's induction does not produce a safe or desirable reduction in tacrolimus exposure.
Option B: Option B is incorrect because elexacaftor does not inhibit the renal organic anion transporter or any other transporter responsible for tacrolimus excretion in a way that compensates for lumacaftor's CYP3A4 induction; no pharmacokinetic balancing mechanism of this kind exists in the ETI combination.
Option C: Option C is incorrect because tezacaftor and elexacaftor do not induce CYP3A4; only lumacaftor among the approved CFTR correctors is a strong CYP3A4 inducer, and this is precisely the pharmacokinetic property that distinguishes lumacaftor-ivacaftor from tezacaftor-ivacaftor and ETI in the context of CYP3A4-sensitive co-medications.
Option D: Option D is incorrect because ivacaftor is not a clinically significant CYP3A4 inhibitor at therapeutic doses; there is no established offsetting mechanism by which ivacaftor's presence in the triple combination neutralizes lumacaftor's CYP3A4 induction, and this rationale is pharmacologically unfounded.
6. A 30-year-old man with cystic fibrosis (CF) homozygous for F508del has a baseline FEV1% predicted of 28% and is initiated on lumacaftor-ivacaftor because elexacaftor-tezacaftor-ivacaftor (ETI) is not available at his center. Within 5 days of starting lumacaftor-ivacaftor he develops acute chest tightness, worsening dyspnea, and a 6% absolute decrease in FEV1% predicted. Sputum cultures show no new pathogens. Which of the following best describes the clinical situation, the population at highest risk for this adverse effect, and why ETI would have been a preferable alternative?
A) The presentation represents an expected lumacaftor-ivacaftor response in patients with severe baseline lung disease in which rapid CFTR correction triggers mucus mobilization from chronically obstructed airways; the worsening FEV1 is caused by mobilized mucus temporarily obstructing smaller airways, and the correct management is to intensify airway clearance and continue lumacaftor-ivacaftor at full dose.
B) Chest tightness and acute FEV1 decline are a recognized respiratory adverse effect of lumacaftor-ivacaftor that occurs with the highest frequency and severity in patients with FEV1% predicted below 40%; the mechanism is incompletely understood but is specific to lumacaftor-containing regimens. Lumacaftor-ivacaftor should be held while symptoms are evaluated, and ETI would have been preferable because neither elexacaftor nor tezacaftor is associated with this lumacaftor-specific respiratory adverse effect, making ETI better tolerated in patients with severe baseline lung disease.
C) The presentation is consistent with ivacaftor-induced bronchospasm mediated by excessive chloride secretion into an airway already compromised by severe obstruction; this adverse effect is equally common with all ivacaftor-containing regimens including tezacaftor-ivacaftor and ETI, so switching to ETI would not reduce the respiratory adverse effect risk.
D) Acute FEV1 decline after lumacaftor-ivacaftor initiation in a patient with FEV1% predicted below 30% is the expected marker of treatment response rather than an adverse effect; a transient FEV1 decrease of 5–10% in the first 2 weeks reflects airway remodeling as CFTR function is restored, and the patient should be reassured and the drug continued without dose modification.
E) The FEV1 decline is caused by lumacaftor's CYP3A4 induction reducing plasma concentrations of inhaled corticosteroids the patient may be taking, worsening underlying airway inflammation; the correct management is to increase the inhaled corticosteroid dose by 50% to compensate for lumacaftor-driven induction of corticosteroid metabolism while continuing lumacaftor-ivacaftor.
ANSWER: B
Rationale:
Chest tightness, worsening dyspnea, and acute decline in FEV1% predicted are a recognized and clinically important respiratory adverse effect associated specifically with lumacaftor-ivacaftor (Orkambi). This adverse effect occurs across the treated population but is particularly frequent and severe in patients with more advanced baseline lung disease — especially those with FEV1% predicted below 40% — making this patient with FEV1% predicted of 28% among those at highest risk. The precise mechanism remains incompletely characterized but is thought to involve lumacaftor-related airway inflammatory or bronchospastic responses rather than a pharmacokinetically mediated effect. Importantly, this respiratory adverse effect is specific to lumacaftor-containing regimens and is not seen with the same frequency or severity with tezacaftor-ivacaftor or ETI, because neither tezacaftor nor elexacaftor produces the respiratory tolerability problem associated with lumacaftor. This is one of the principal clinical reasons ETI is the preferred regimen for F508del patients when available, particularly in those with severe baseline disease who are least able to tolerate acute FEV1 reductions. When the adverse effect occurs, lumacaftor-ivacaftor should be temporarily held, symptoms allowed to resolve, and a decision made about rechallenge (sometimes with pre-treatment bronchodilators or gradual dose escalation) or transition to an alternative regimen under specialist guidance.
Option A: Option A is incorrect because the acute FEV1 decline and chest tightness do not represent mucus mobilization from corrected airways; this mechanism is not established, and continuing full-dose lumacaftor-ivacaftor in a symptomatic patient with acute respiratory deterioration is not appropriate management.
Option C: Option C is incorrect because the respiratory adverse effect is specific to lumacaftor-containing regimens; ivacaftor itself is not the driver, and ETI (which contains tezacaftor and elexacaftor rather than lumacaftor) does not share this adverse effect profile.
Option D: Option D is incorrect because acute FEV1 decline after lumacaftor-ivacaftor initiation is not an expected or acceptable marker of treatment response; it is a recognized drug adverse effect that warrants holding the drug and evaluating the patient rather than reassuring them and continuing treatment.
Option E: Option E is incorrect because inhaled corticosteroid concentrations are not meaningfully reduced by lumacaftor-driven CYP3A4 induction at standard inhaled doses; inhaled corticosteroids undergo primarily pulmonary and airway metabolism rather than systemic CYP3A4-mediated first-pass metabolism, and this mechanism is not the cause of the respiratory adverse effect.
7. A 44-year-old man with cystic fibrosis (CF) homozygous for F508del with long-standing severe lung disease (baseline FEV1% predicted 31%, bilateral bronchiectasis, chronic Pseudomonas aeruginosa colonization) initiates elexacaftor-tezacaftor-ivacaftor (ETI). After 6 months, his sweat chloride has fallen from 98 mmol/L to 22 mmol/L — normalizing completely — but his FEV1% predicted has improved by only 4 percentage points (from 31% to 35%). He is disappointed and asks whether ETI is "not working" given the small lung function improvement compared with what he has read about in younger patients. Which of the following best explains the discordant biomarker responses and provides the most accurate clinical interpretation?
A) The sweat chloride normalization indicates ETI is achieving near-complete CFTR functional restoration at the molecular level, and the FEV1 improvement of 4 percentage points confirms that ETI is ineffective at reversing established lung disease in older patients; he should be referred for lung transplant evaluation immediately because ETI has failed to produce meaningful clinical benefit in his case.
B) The discordant responses indicate that the sweat chloride assay is unreliable in older CF patients with established disease because chronic airway inflammation alters sweat gland CFTR expression independently of modulator therapy; the 22 mmol/L value likely overestimates CFTR functional restoration, and FEV1 is the more trustworthy indicator of true pharmacological response.
C) Sweat chloride normalization and modest FEV1 improvement are inconsistent findings that suggest ETI is producing off-target pharmacological effects unrelated to CFTR rescue; the improvement in sweat chloride reflects ETI's anti-inflammatory properties in sweat ducts rather than CFTR channel restoration, and further pharmacogenomic testing is warranted to assess whether this patient carries a modifier mutation reducing ETI's pulmonary efficacy.
D) Sweat chloride normalization confirms that ETI is producing robust CFTR functional restoration at the molecular level — sweat chloride reflects CFTR activity in sweat duct epithelium which is free of structural damage — while the modest FEV1 improvement reflects the fact that pre-existing bronchiectasis, mucus plugging, airway wall fibrosis, and chronic infection produce a structural lung disease burden that constrains how much FEV1 can improve regardless of the degree of CFTR functional rescue achieved; the two biomarkers measure different things, and the clinical benefit of ETI extends well beyond FEV1 to include reduced exacerbation frequency, stabilized disease trajectory, and improved quality of life.
E) The 4 percentage-point FEV1 improvement in a patient with FEV1% predicted of 31% is consistent with the expected response for his severity of baseline disease; sweat chloride normalization indicates maximal CFTR restoration, and the combined biomarker profile confirms ETI is working optimally; he should expect FEV1 to continue improving by 4 to 6 percentage points per year for the next 3 to 5 years as airway remodeling progresses.
ANSWER: D
Rationale:
The discordance between dramatic sweat chloride normalization and modest FEV1 improvement is a recognized and clinically important pattern in ETI-treated patients with advanced pre-existing lung disease, and understanding it is essential for accurate patient counseling. Sweat chloride concentration reflects CFTR channel activity in sweat duct epithelium — tissue that has no structural damage from CF lung disease and no accumulated fibrosis, bronchiectasis, or chronic infection. When ETI restores CFTR function at the molecular level, sweat chloride responds faithfully and rapidly, often normalizing to below 40 mmol/L within weeks of initiation. FEV1, by contrast, is a measure of airflow through the pulmonary airways and is constrained by the cumulative structural damage those airways have sustained over decades of CFTR dysfunction: bronchiectatic dilation and wall destruction, mucus plugging, fibrotic airway remodeling, and chronic endobronchial infection with Pseudomonas aeruginosa producing biofilm and ongoing inflammation. These structural changes do not reverse when CFTR function is restored — as established by CT and long-term follow-up data from ETI studies — and therefore impose a ceiling on achievable FEV1 improvement that is unrelated to the degree of pharmacological CFTR rescue. This patient's sweat chloride of 22 mmol/L confirms that ETI is working at the molecular level; his modest FEV1 gain reflects his pre-existing structural disease burden, not drug failure. His clinical benefit from ETI includes reduced exacerbation frequency, stabilized disease trajectory, improved nutritional status, and quality-of-life gains that extend far beyond the spirometric change.
Option A: Option A is incorrect because a 4 percentage-point FEV1 improvement in a patient with severe baseline disease and extensive bronchiectasis is not evidence of ETI failure warranting immediate transplant referral; the sweat chloride normalization confirms molecular CFTR rescue, and the modest FEV1 gain reflects structural constraints, not absence of drug effect.
Option B: Option B is incorrect because sweat chloride is a reliable and validated biomarker of CFTR function that is not systematically affected by airway inflammation in the manner described; the discordance reflects the structural-functional distinction explained above, not assay unreliability.
Option C: Option C is incorrect because ETI's CFTR rescue mechanism explains both biomarker responses coherently; sweat chloride normalization is not an off-target anti-inflammatory effect, and no pharmacogenomic modifier mutation testing is warranted based on this predictable response pattern.
Option E: Option E is incorrect because continued progressive FEV1 improvement of 4 to 6 percentage points per year over 3 to 5 years is not the established pattern in ETI-treated adults with severe disease; established bronchiectasis does not undergo ongoing favorable remodeling with sustained ETI therapy, and projecting year-over-year gains overstates the expected long-term trajectory.
8. A clinical pharmacology fellow is reviewing the VX-445-102 trial data showing that elexacaftor-tezacaftor-ivacaftor (ETI) produced a 10.0 percentage-point improvement in FEV1% predicted compared with tezacaftor-ivacaftor alone in F508del homozygous patients. She asks why adding elexacaftor to a regimen that already contains a corrector (tezacaftor) and a potentiator (ivacaftor) produces such substantial additional benefit — what does elexacaftor add that tezacaftor has not already accomplished? Which of the following best explains the mechanistic basis for the additive efficacy of elexacaftor over tezacaftor in the triple combination?
A) Elexacaftor binds to a site on F508del CFTR that is structurally distinct from tezacaftor's binding site; simultaneous engagement of two different regions of the misfolded F508del CFTR protein by both correctors produces cooperative conformational stabilization substantially greater than either corrector achieves alone, allowing a much larger fraction of F508del CFTR to escape endoplasmic reticulum-associated degradation (ERAD) and traffic to the apical membrane, where ivacaftor potentiates its gating.
B) Elexacaftor acts at the Golgi apparatus rather than the endoplasmic reticulum (ER), rescuing F508del CFTR that has already partially escaped ER quality control but stalls during post-translational glycosylation in the Golgi; by acting at a trafficking step downstream of tezacaftor's ER-based action, elexacaftor addresses a distinct bottleneck that tezacaftor leaves unresolved.
C) Elexacaftor inhibits the proteasomal degradation complex that destroys misfolded CFTR after ubiquitination, preventing ERAD of F508del CFTR that tezacaftor has stabilized but not fully rescued; by blocking proteasomal clearance, elexacaftor increases the pool of partially stabilized F508del CFTR available for trafficking without requiring direct CFTR binding.
D) Elexacaftor is a CFTR potentiator with a binding site on the channel pore distinct from ivacaftor's binding site; its addition to the regimen produces additive increases in channel open probability beyond what ivacaftor achieves alone, explaining the incremental FEV1 benefit without requiring a second corrector mechanism.
E) Elexacaftor acts by suppressing the expression of the Hsp90 co-chaperone CHIP (C-terminus of Hsc70-interacting protein) that targets tezacaftor-stabilized F508del CFTR for residual ubiquitination; by silencing this secondary ubiquitin ligase, elexacaftor prevents degradation of F508del CFTR that tezacaftor has already partially rescued from primary ER quality control surveillance.
ANSWER: A
Rationale:
Elexacaftor is a next-generation CFTR corrector whose binding site on the F508del CFTR protein is structurally and spatially distinct from the binding site of tezacaftor. When both correctors are present simultaneously in the triple combination, they engage two different regions of the misfolded F508del CFTR protein concurrently — elexacaftor and tezacaftor each stabilize a different domain or interface of the misfolded protein. This dual engagement produces cooperative conformational stabilization of F508del CFTR in the endoplasmic reticulum (ER) that is substantially greater than the stabilization achieved by either corrector alone, reducing recognition by the ER quality control machinery (including the Hsp70/Hsp90 chaperone-cochaperone complex) and markedly decreasing the fraction of F508del CFTR targeted for proteasomal degradation through ER-associated degradation (ERAD). The result is that a much larger absolute amount of F508del CFTR completes folding, transits the Golgi, and reaches the apical epithelial membrane, where ivacaftor then potentiates the gating of the corrected protein. This dual-corrector synergy is the mechanistic explanation for the 10-percentage-point FEV1 advantage of ETI over tezacaftor-ivacaftor in F508del homozygotes and for the 13.8-percentage-point advantage in F508del/minimal-function heterozygotes versus placebo. The principle — that two correctors binding distinct sites produce cooperative rescue greater than additive of their individual effects — is the conceptual foundation of the triple combination's superior efficacy.
Option B: Option B is incorrect because elexacaftor does not act at the Golgi to rescue CFTR that has stalled there; the corrector mechanism of both tezacaftor and elexacaftor is in the ER, where they stabilize misfolded CFTR before it can be degraded or complete trafficking; elexacaftor's added benefit is from its distinct ER-level binding site, not a downstream Golgi-level action.
Option C: Option C is incorrect because elexacaftor does not act by inhibiting the proteasomal degradation complex; it binds directly to CFTR protein to stabilize its conformation, which is a distinct mechanism from blocking the proteasome itself; proteasome inhibition would have broad non-selective effects on cellular protein quality control that are not part of elexacaftor's pharmacology.
Option D: Option D is incorrect because elexacaftor is a CFTR corrector, not a potentiator; it acts at the ER level on protein folding and trafficking, not at the apical membrane to increase channel open probability; the potentiator role in ETI is exclusively ivacaftor's.
Option E: Option E is incorrect because elexacaftor does not act by suppressing CHIP or any other specific ubiquitin ligase; its mechanism is direct CFTR binding and conformational stabilization, not indirect protection from secondary ubiquitination by a co-chaperone target.
9. A 36-year-old man with cystic fibrosis (CF) carries G542X on one allele and W1282X on the other — both class I nonsense mutations. He has no F508del allele. His FEV1% predicted has declined from 38% to 29% over the past 18 months despite maximal bronchodilator therapy, aggressive airway clearance, and prompt antibiotic treatment of pulmonary exacerbations. He asks about CFTR modulators. His CF team must also address his declining lung function trajectory. Which of the following represents the most complete and accurate integrated management plan for this patient?
A) Elexacaftor-tezacaftor-ivacaftor (ETI) should be initiated immediately on a compassionate use basis given the rapid FEV1 decline, because the FDA allows off-label ETI in class I mutation patients with FEV1% predicted below 30% when no other disease-modifying option exists; this should be combined with lung transplant evaluation given the severity of his lung function impairment.
B) Ivacaftor monotherapy is appropriate for this patient because W1282X, while primarily a class I nonsense mutation, produces a truncated CFTR protein with sufficient length to retain a partially functional gating domain that responds to ivacaftor potentiation; the truncated protein reaches the membrane in small but therapeutically significant amounts in some W1282X patients, making a 12-week ivacaftor trial clinically reasonable.
C) No currently approved CFTR modulator is indicated for this patient because both mutations eliminate functional CFTR protein through nonsense-mediated mRNA decay (NMD), leaving no pharmacological target for any approved corrector or potentiator; management should include continued aggressive airway clearance, inhaled mucoactive agents, prompt antibiotic therapy for exacerbations, nutritional optimization, and active referral for lung transplant evaluation given FEV1% predicted of 29% on a declining trajectory, with clinical trial enrollment actively discussed.
D) Tezacaftor-ivacaftor should be initiated because recent FDA guidance has reclassified W1282X as a residual function mutation in patients who retain detectable CFTR mRNA expression on nasal epithelial RNA analysis; this patient should have nasal RNA sampling performed, and if residual mRNA is detected, tezacaftor-ivacaftor is the appropriate corrector-potentiator combination.
E) The priority intervention is monthly intravenous immunoglobulin (IVIG) infusions to reduce neutrophilic airway inflammation and slow FEV1 decline while CFTR-directed therapy options are being explored; IVIG has demonstrated a 30% reduction in pulmonary exacerbation rate in class I mutation CF patients in recent phase 2 trials and is appropriate as a bridge therapy.
ANSWER: C
Rationale:
Both G542X and W1282X are class I CFTR mutations — nonsense mutations that introduce premature stop codons into the CFTR mRNA and trigger nonsense-mediated mRNA decay (NMD), resulting in absent or severely truncated CFTR protein with no functional channel present at the apical epithelial membrane. No currently approved CFTR modulator — corrector (lumacaftor, tezacaftor, elexacaftor) or potentiator (ivacaftor) — has a pharmacological target in this patient, because correctors require a misfolded but translatable CFTR protein in the ER and potentiators require surface-expressed CFTR channels at the membrane. The appropriate management integrates two distinct imperatives: ongoing best supportive care (airway clearance therapy, inhaled dornase alfa, inhaled hypertonic saline, aggressive antibiotic treatment of exacerbations, pancreatic enzyme replacement, fat-soluble vitamin supplementation, and nutritional optimization) and active lung transplant referral. With FEV1% predicted declining from 38% to 29% over 18 months, this patient is approaching and has arguably crossed the threshold at which transplant evaluation is strongly indicated — generally considered FEV1% predicted below 30% or rapid decline — and referral should not be deferred. Active discussion of clinical trial enrollment in investigational class I therapies (read-through agents, RNA-targeted therapies, nonsense suppression strategies) is also appropriate.
Option A: Option A is incorrect because there is no FDA compassionate use pathway for ETI in class I homozygotes based on low FEV1; ETI has no pharmacological rationale or regulatory basis for use in patients with no F508del allele, and initiating it off-label in this setting is not appropriate clinical practice.
Option B: Option B is incorrect because W1282X is a class I nonsense mutation that undergoes NMD; while some residual read-through translation may occur at low levels in certain NMD-escaping contexts, this is insufficient for clinically meaningful ivacaftor potentiation, and a therapeutic ivacaftor trial is not a guideline-supported management strategy for W1282X homozygotes or compound heterozygotes outside of clinical trials.
Option D: Option D is incorrect because no FDA guidance has reclassified W1282X as a residual function mutation approving tezacaftor-ivacaftor; such a reclassification does not exist in current labeling, and nasal epithelial RNA analysis is a research tool, not a clinical standard for modulator eligibility determination.
Option E: Option E is incorrect because monthly IVIG infusions are not approved or guideline-supported for reducing pulmonary exacerbations in CF patients with class I mutations; no phase 2 trial demonstrating 30% exacerbation reduction with IVIG in this population exists in the established CF literature.
10. A CF care coordinator reviews the medication list of a 31-year-old woman with cystic fibrosis (CF) homozygous for F508del on elexacaftor-tezacaftor-ivacaftor (ETI) who is prescribed both inhaled dornase alfa (once daily) and inhaled hypertonic saline (7% NaCl, twice daily) in addition to her modulator. The coordinator asks why two separate inhaled agents are used when both seem to target mucus. A medical student is asked to explain what each agent contributes and why both may remain useful even after CFTR function is substantially restored by ETI. Which of the following correctly distinguishes the mechanisms of the two agents and explains why both may continue to provide complementary benefit?
A) Dornase alfa and hypertonic saline have identical mechanisms of action — both work by osmotically hydrating the airway surface liquid layer — but act at different airway levels; dornase alfa preferentially hydrates small airways while hypertonic saline hydrates large central airways, justifying dual therapy to achieve full airway coverage in patients with diffuse bronchiectasis.
B) Dornase alfa thins mucus by activating calcium-dependent chloride channels that restore airway surface liquid hydration independently of CFTR, while hypertonic saline cleaves mucin disulfide bonds to reduce mucus gel viscosity through a reductive chemistry mechanism; together they address both the ionic and structural components of CF mucus abnormality.
C) Hypertonic saline degrades extracellular DNA released by neutrophils in infected airways, reducing mucus viscosity by cleaving the DNA polymer network, while dornase alfa restores airway surface liquid hydration through osmotic water flux; each agent addresses the component of CF mucus pathology that the other cannot target.
D) Both agents work primarily by reducing mucus viscosity through complementary anti-inflammatory mechanisms — dornase alfa inhibits neutrophil elastase while hypertonic saline scavenges reactive oxygen species produced by activated neutrophils — with the reduction in airway inflammation secondarily improving mucus rheology and clearance.
E) Dornase alfa is a recombinant DNase that degrades extracellular DNA released by neutrophils in chronically infected CF airways, reducing mucus viscosity and stiffness through DNA polymer cleavage; hypertonic saline creates an osmotic gradient that draws water from the airway wall into the airway lumen, rehydrating the mucus layer and periciliary liquid and restoring mucociliary transport velocity; the two agents address distinct pathological contributors to CF mucus — DNA-driven viscosity and airway surface dehydration, respectively — and may both continue to provide benefit in patients with established bronchiectasis even after CFTR is pharmacologically restored by ETI.
ANSWER: E
Rationale:
Dornase alfa and inhaled hypertonic saline address two mechanistically distinct pathological contributors to CF airway mucus dysfunction, which is why both may remain useful even after ETI partially restores CFTR function. Dornase alfa is a recombinant human deoxyribonuclease I (DNase I) that catalyzes the hydrolytic cleavage of the phosphodiester backbone of extracellular deoxyribonucleic acid (DNA) into smaller fragments. In chronically infected CF airways, the massive neutrophilic inflammatory response to bacterial colonization (particularly Pseudomonas aeruginosa) releases large quantities of high-molecular-weight DNA from lysed neutrophils; this extracellular DNA becomes entangled in the mucus gel matrix, forming a DNA-mucin network that dramatically increases mucus viscosity and elasticity. Dornase alfa cleaves this DNA network, reducing sputum viscosity and improving mucociliary and cough-driven clearance. Inhaled hypertonic saline (7% NaCl) acts through a completely different mechanism: it creates a steep osmotic gradient between the hyperosmolar airway lumen and the isotonic submucosal tissue, drawing water osmotically from the tissue into the airway lumen; this rehydrates the mucus layer and periciliary liquid layer, restoring the aqueous layer in which cilia beat and improving mucociliary transport velocity. In patients with established bronchiectasis and ongoing airway infection — as in this patient — both the DNA-driven viscosity problem and the surface dehydration problem persist despite ETI-mediated CFTR rescue, justifying continued dual mucoactive therapy with individualized reassessment.
Option A: Option A is incorrect because dornase alfa and hypertonic saline do not have identical mechanisms; dornase alfa cleaves DNA and hypertonic saline acts osmotically, and they are not distinguished by airway level (small vs large) but by mechanism.
Option B: Option B is incorrect because dornase alfa does not activate calcium-dependent chloride channels, and hypertonic saline does not cleave mucin disulfide bonds; these mechanisms belong to other agents (TMEM16A activators and N-acetylcysteine, respectively).
Option C: Option C is incorrect because the mechanisms are exactly reversed: dornase alfa degrades DNA (not hypertonic saline), and hypertonic saline provides osmotic hydration (not dornase alfa); the option's assignments are transposed.
Option D: Option D is incorrect because neither dornase alfa nor hypertonic saline acts primarily through anti-inflammatory mechanisms; dornase alfa does not inhibit neutrophil elastase (that is alpha-1 antitrypsin's mechanism), and hypertonic saline does not scavenge reactive oxygen species as its primary therapeutic action.
11. A 19-year-old man with cystic fibrosis (CF) is found to carry one F508del allele and one R117H allele. R117H is a class IV CFTR mutation associated with reduced chloride conductance through the channel pore. His CF team explains that ivacaftor monotherapy is not approved for his F508del allele but that tezacaftor-ivacaftor is appropriate for his genotype. His medical student asks why R117H — which is not a gating mutation — responds to ivacaftor, a potentiator, and why potentiator therapy without a corrector is sufficient for class IV mutations but not for the F508del allele. Which of the following best answers this question?
A) R117H is a class IV mutation that reduces CFTR conductance through the channel pore; ivacaftor improves pore conductance by physically widening the chloride permeation pathway through a direct conformational change in the transmembrane domains, which is the same mechanism by which ivacaftor benefits class III gating mutations — the common thread is that the CFTR protein is present at the surface and ivacaftor can physically alter channel architecture to increase chloride throughput.
B) R117H CFTR folds normally and traffics to the apical membrane in near-normal quantities — reaching the pharmacological target site for ivacaftor — but has reduced chloride conductance through its pore and reduced channel open probability; ivacaftor increases CFTR channel open probability (gating activity), which provides meaningful benefit even in class IV mutations where the protein is surface-expressed, without requiring corrector-mediated trafficking rescue; F508del CFTR, by contrast, undergoes extensive ER-associated degradation and reaches the surface in negligible amounts without a corrector, so potentiation alone is futile.
C) R117H is classified as a class IV mutation but actually has a primary gating defect identical to G551D that produces near-zero channel open probability; ivacaftor provides benefit because R117H's gating defect responds to potentiation; it is therefore pharmacologically identical to a class III mutation despite its formal mutation class designation, and the class IV classification is a regulatory artifact rather than a mechanistic distinction.
D) Ivacaftor is effective for R117H because R117H produces a CFTR protein with a processing defect similar to F508del but substantially less severe, allowing a small fraction of R117H CFTR to escape ER quality control and reach the membrane without a corrector; ivacaftor potentiates this escaped population; F508del's processing defect is more severe and requires corrector assistance before ivacaftor has any meaningful target.
E) Class IV mutations including R117H respond to ivacaftor monotherapy because the reduced conductance phenotype triggers a compensatory increase in CFTR protein production through an unfolded protein response (UPR) mechanism, placing larger than normal amounts of CFTR at the apical membrane; ivacaftor then amplifies the activity of this upregulated CFTR population; F508del CFTR does not trigger UPR-mediated upregulation because its misfolding is recognized and silenced before the UPR pathway is activated.
ANSWER: B
Rationale:
The key to understanding why ivacaftor monotherapy provides benefit for class IV mutations (such as R117H) without requiring a corrector — while being ineffective as monotherapy for F508del (class II) — lies in the availability of the pharmacological target at the apical membrane. R117H CFTR carries a mutation in the transmembrane domains that reduces conductance through the chloride channel pore and also reduces channel open probability; critically, R117H CFTR folds and traffics normally to the apical epithelial cell membrane in near-normal or adequate amounts, because the mutation does not substantially impair ER folding or transit through the quality control machinery. The pharmacological target for ivacaftor — surface-expressed CFTR with suboptimal channel activity — is therefore available. Ivacaftor increases the open probability of CFTR channels already at the membrane, providing benefit to class IV mutations by augmenting the gating component of their dysfunction and amplifying the chloride conductance that does occur through the pore. A corrector is unnecessary because the protein successfully completes trafficking without assistance. F508del CFTR, by contrast, undergoes extensive ER-associated degradation (ERAD) due to severe misfolding, and reaches the apical membrane in negligible amounts in the absence of a corrector; ivacaftor has essentially no surface-expressed F508del CFTR to potentiate, making monotherapy futile. This fundamental distinction — whether CFTR reaches the surface independently — determines whether potentiation alone is sufficient or whether corrector rescue is a prerequisite.
Option A: Option A is incorrect because ivacaftor does not physically widen the chloride permeation pathway or alter transmembrane domain architecture; its mechanism is to increase channel open probability (gating), not to structurally remodel the pore conductance pathway — conductance per open channel is not substantially changed by ivacaftor.
Option C: Option C is incorrect because R117H does not have a gating defect identical to G551D; its primary defect is reduced conductance and somewhat reduced open probability in the context of normal trafficking, not the severe gating failure of G551D; the class IV designation is mechanistically meaningful, not a regulatory artifact.
Option D: Option D is incorrect because R117H is not a class II processing mutation; it does not misfold and does not undergo significant ER retention; the distinction from F508del is not a matter of degree of ER processing defect severity but a categorical difference in mutation class (trafficking vs conductance).
Option E: Option E is incorrect because class IV mutations do not trigger compensatory UPR-mediated CFTR upregulation as their basis for ivacaftor responsiveness; the normal trafficking of class IV CFTR proteins is intrinsic to the mutation's molecular defect profile, not a UPR-driven compensatory mechanism.
12. A 26-year-old woman with cystic fibrosis (CF) homozygous for F508del on elexacaftor-tezacaftor-ivacaftor (ETI) is diagnosed with CF-related diabetes (CFRD) after an oral glucose tolerance test (OGTT) demonstrates a 2-hour plasma glucose of 241 mg/dL. Her BMI is 18.1 kg/m², she has lost 4 kg over the past year, and she uses dornase alfa and chest physiotherapy daily. Her endocrinologist proposes initiating an oral antidiabetic agent before considering insulin. Which of the following best explains why insulin is the preferred first-line treatment for CFRD, integrating the pathophysiology, the specific limitations of oral antidiabetic agents in this context, and the potential anabolic benefit of insulin therapy?
A) Insulin is preferred because all oral antidiabetic agents are contraindicated by the FDA specifically in CF patients due to pharmacokinetic interactions with inhaled tobramycin and dornase alfa that have been identified in post-marketing surveillance; the CF drug interaction profile makes any oral agent unsafe regardless of its mechanism of action.
B) Insulin is preferred because CFRD is classified as a form of type 1 diabetes mellitus by current guidelines, and the American Diabetes Association (ADA) explicitly recommends insulin as the sole approved therapy for type 1 diabetes in all patient populations including those with CF-related pancreatic destruction.
C) Oral antidiabetic agents are avoided in CFRD solely because of the malabsorption that characterizes CF exocrine pancreatic insufficiency; since all oral drugs are incompletely absorbed in CF patients due to absent pancreatic enzymes required for intestinal drug processing, they do not achieve therapeutic plasma concentrations, whereas insulin bypasses the gastrointestinal tract entirely.
D) CFRD results from progressive islet cell destruction by pancreatic exocrine fibrosis, producing relative insulin deficiency rather than the insulin resistance that drives type 2 diabetes; insulin directly replaces the deficient hormone and may provide anabolic benefit — promoting protein synthesis and mitigating the muscle catabolism and malnutrition that compound CF morbidity — while oral agents such as metformin (which targets insulin resistance) and sulfonylureas (which stimulate residual beta-cell secretion in an already depleted pancreas) are mechanistically mismatched to CFRD pathophysiology and carry risks including lactic acidosis and hypoglycemia respectively that are disproportionate in this nutritionally vulnerable population.
E) Insulin is preferred in CFRD solely because of the need for flexible dosing around the highly variable caloric intake, frequent meal skipping, and gastroparesis common in CF patients; rapid-acting insulin analogs can be titrated to match actual carbohydrate intake at each meal, whereas fixed-dose oral agents cannot accommodate the erratic nutritional patterns of CF patients and produce hypoglycemia during periods of reduced intake.
ANSWER: D
Rationale:
CF-related diabetes (CFRD) results from progressive destruction of pancreatic islet cells — including insulin-secreting beta cells — by the advancing exocrine pancreatic fibrosis that characterizes CF, producing a state of relative insulin deficiency. This pathophysiology is categorically different from type 2 diabetes mellitus, in which the primary defect is peripheral tissue insulin resistance with compensatory hyperinsulinemia. Insulin therapy is preferred in CFRD for multiple integrated reasons. First, it directly replaces the deficient hormone, addressing the primary pathophysiological defect. Second, insulin has potential anabolic benefits that are clinically important in CF patients who are prone to malnutrition, muscle wasting, and impaired nitrogen balance — insulin promotes protein synthesis and reduces muscle catabolism, providing benefit beyond glycemic control in a population where nutritional status directly affects pulmonary outcomes. Third, oral antidiabetic agents have significant mechanistic and safety limitations in CFRD: metformin acts primarily by reducing hepatic gluconeogenesis and improving insulin sensitivity — mechanisms targeted at insulin resistance, not insulin deficiency — making it pharmacologically mismatched to CFRD's primary defect; additionally, metformin carries a risk of lactic acidosis that is heightened in CF patients with chronic hypoxia from advanced lung disease, reduced renal reserve, and nutritional compromise. Sulfonylureas stimulate residual beta-cell insulin secretion, but in a pancreas with progressive islet destruction and already depleted beta-cell mass, the secretory reserve available for stimulation is limited and the risk of hypoglycemia in a nutritionally vulnerable patient with erratic intake is clinically significant.
Option A: Option A is incorrect because no FDA-wide contraindication to all oral antidiabetic agents in CF patients based on inhaled drug interactions exists; the preference for insulin is based on pathophysiological match and clinical benefit, not categorical drug interaction contraindications.
Option B: Option B is incorrect because CFRD is not classified as type 1 diabetes mellitus; it has a distinct pathophysiology (fibrosis-driven islet destruction rather than autoimmune beta-cell attack) and its own clinical guidelines; the statement about ADA classification is inaccurate.
Option C: Option C is incorrect because malabsorption in CF is specific to fat and fat-soluble nutrients due to lipase deficiency and does not prevent the absorption of water-soluble oral medications including metformin; the premise that oral drugs are not absorbed in CF due to absent pancreatic enzymes is pharmacologically incorrect.
Option E: Option E is incorrect because while flexible insulin dosing around variable caloric intake is a genuine clinical advantage, it is not the sole or primary reason insulin is preferred in CFRD; the integrated pathophysiological rationale — insulin deficiency, anabolic benefit, and oral agent limitations — is the complete clinical justification.
13. A pediatric pulmonologist is counseling the parents of a 26-month-old girl recently diagnosed with CF who is homozygous for F508del. The parents ask why the team is recommending elexacaftor-tezacaftor-ivacaftor (ETI) at age 2, given that their daughter currently has no respiratory symptoms and a normal chest radiograph. They question whether it would be safer to wait until she shows evidence of lung disease before exposing her to a complex three-drug regimen. Which of the following best explains the pharmacological and clinical rationale for initiating ETI at age 2 in this asymptomatic patient?
A) The rationale for initiating ETI at age 2 in an asymptomatic F508del homozygous child rests on the established irreversibility of CF airway structural damage: even in the absence of clinical symptoms, subclinical airway inflammation, early mucus plugging, and microbiological colonization begin in infancy, and the bronchiectasis, airway wall fibrosis, and chronic infection that result from years of CFTR dysfunction do not reverse when ETI is eventually initiated; by restoring CFTR function before cumulative structural injury accrues — during the window when the airway architecture is still intact — early ETI initiation can prevent damage that pharmacological rescue cannot undo, providing a clinical benefit far greater than any achievable by waiting for symptomatic disease to develop.
B) ETI initiation at age 2 is recommended primarily to prevent CF-related diabetes (CFRD) rather than lung disease; pancreatic islet cell destruction from pancreatic fibrosis begins in the first year of life and progresses most rapidly between ages 2 and 5, and restoring CFTR function in pancreatic ductal epithelium during this window halts islet destruction and prevents CFRD in more than 90% of patients who start ETI before age 3.
C) The age 2 ETI approval is based on regulatory extrapolation from adult pharmacokinetic data without pediatric efficacy trials; the recommendation to initiate at age 2 reflects conservative regulatory practice rather than clinical evidence of benefit in young children, and it is clinically reasonable to delay initiation until age 5 to 6, when robust pediatric spirometry can be performed to confirm ETI is producing measurable lung function benefit before committing to long-term therapy.
D) ETI is initiated at age 2 primarily to prevent CF-related liver disease, which is the most common cause of early mortality in CF patients; CFTR dysfunction in biliary epithelial cells produces inspissated bile leading to cirrhosis by age 5 to 10 in untreated patients, and ETI prevents biliary fibrosis by restoring CFTR-mediated bicarbonate secretion in cholangiocytes during the critical window before cirrhotic remodeling begins.
E) The rationale for age 2 initiation is primarily pharmacoeconomic: early initiation reduces the cumulative cost of managing CF complications including hospitalizations, intravenous antibiotic courses, and nutritional interventions by preventing exacerbations during childhood, and the FDA approval was driven by health technology assessment data showing cost-effectiveness thresholds are met only when ETI is initiated before age 3.
ANSWER: A
Rationale:
The fundamental pharmacological and clinical rationale for initiating ETI as early as possible — and the basis for the FDA approval extending to age 2 — is the irreversibility of CF airway structural damage once it has occurred. Although this child appears clinically well with a normal chest radiograph at 26 months, research using sensitive imaging techniques including chest CT and bronchoalveolar lavage studies has demonstrated that subclinical airway inflammation, early neutrophilic airway disease, mucus plugging, and microbiological colonization can begin in infancy in F508del homozygous patients — often before any clinical symptoms are apparent. The structural airway remodeling that results from cumulative CFTR dysfunction — bronchiectatic airway dilation, fibrosis and destruction of airway wall elastic and muscular components, and establishment of chronic endobronchial bacterial biofilm — does not reverse when CFTR function is restored by ETI, as established by CT imaging studies in ETI-treated adults and older children. A patient who begins ETI at age 25 with established bronchiectasis retains that structural damage permanently; a patient who begins ETI at age 2 before bronchiectasis has developed has the opportunity to prevent that damage from ever accruing. This prevention-over-rescue argument is the core clinical rationale for early initiation and directly answers the parents' question: waiting for symptomatic disease to develop means waiting for irreversible structural injury to occur, at which point ETI can slow further progression but cannot undo the cumulative harm.
Option B: Option B is incorrect because while ETI may have beneficial effects on pancreatic function and CFRD progression, preventing CFRD is not the primary rationale for the age 2 approval, and the claim that ETI prevents CFRD in more than 90% of patients starting before age 3 is not an established evidence-based statistic.
Option C: Option C is incorrect because the age 2 approval is not based solely on regulatory extrapolation; pediatric pharmacokinetic and efficacy studies were conducted in children aged 2 to 5 years and informed the label expansion, and delaying initiation until age 5 to 6 to await spirometry is precisely the approach the early initiation rationale argues against.
Option D: Option D is incorrect because while CF-related liver disease is a significant complication, it is not the primary cause of early mortality in CF (respiratory failure is the leading cause), and preventing biliary cirrhosis is not the primary rationale for the age 2 ETI approval.
Option E: Option E is incorrect because the clinical approval rationale is based on prevention of irreversible airway structural damage rather than pharmacoeconomic modeling; while cost-effectiveness is a relevant consideration in formulary and reimbursement decisions, it is not the clinical or regulatory basis for the age 2 FDA approval.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.